Inspired by America’s drive a generation ago to put a man on the moon, MD Anderson’s Moon Shots Program is a highly-concentrated effort to rapidly and dramatically decrease suffering and death in several major cancers, including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung; melanoma; prostate and two cancers linked at the molecular level: triple-negative breast and ovarian. Focused teams are building on new technology and...

On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center. Here he shares his plans for his tenure as president. DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson. DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research as co-director of a new...

On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center. Here he shares his expectations of MD Anderson employees. DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson. DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research as co-director of a...

On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center in Houston, TX. Here he describes his strategy for dealing with Houston's heat. DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson. DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research...

On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center. Here he shares his initial impressions of the organization. DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson. DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research as co-director of a...

On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center. Here he describes his plans for the organization. DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson. DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research as co-director of a new...

On Thursday, Sept. 1, 2011, Ronald DePinho, M.D., began his presidency of MD Anderson Cancer Center. Here he shares his plans for his first day on that job. DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson. DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research as co-director of a new...